(Reuters) – Carmat goes up on the stock market on Monday after announcing that he has crossed the course of 100 establishments of his artificial heart Aeson, the French group specifying having carried out the last two locations successfully last week.
“This very encouraging dynamic confirms Carmat in its ambition to double its sales in 2025, and to gradually establish Aeson® as a reference therapy in the treatment of advanced heart failure,” the group said in a press release.
On the Paris Stock Exchange, around 8:50 am, the title jumped from 10.3% to 0.87 euros, facing its best day since October 2024.
“This CAP, although symbolic, is encouraging for Carmat sales,” said Mohamed Kaabouni, analyst at Portzamparc, in a note.
According to Portzamparc, Carmat needs 500 implants per year to reach profitability, the broker noting that this number was 42 in 2024.
The Aeson de Carmat heart prosthesis is connected to a battery and a controller transported in a pocket, a device whose manufacturing costs around 90,000 euros.
(Written by Elena Smirnova, edited by Augustin Turpin)
Copyright © 2025 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.